Aurobindo Pharma (NSE: AUROPHARMA) reported its second-quarter 2022 earnings results today.
The company had a consolidated net profit of ₹696.71 crores with a decline of 14% compared to the previous year.
Consolidated total revenue from operations during the period was at ₹5,941.92 crores compared to ₹6,483.44 crores for the same period a year ago.
Business performance across most of the segments was robust, aided by gradual pick-up in demand and gradual market share gains. However, profitability was impacted by cost pressure on some of the key raw materials as well as higher logistic costs,” Aurobindo Pharma MD N Govindarajan said.